YOU STOPPED AT: When to Escalate Surveillance: 🔴 PSA >0.05 ng/mL: Repeat PSA in 4-6 weeks 🔴 Confirmed PSA rise:...

COMPLETING YOUR SURVEILLANCE PLAN & LONG-TERM PROGNOSIS

Let me complete the analysis of your current status and what your excellent PSA pattern means for your long-term care.

---

YOUR CURRENT STATUS (As of [date removed])

POST-OPERATIVE TIME: 304 days (approximately 10 months)
CURRENT PSA: 0.007 ng/mL
PSA TRAJECTORY: Excellent - stable at nadir
CANCER STATUS: Cancer-free (confirmed by PSA pattern)
SURGICAL OUTCOME: Excellent - complete resection achieved

─────────────────────────────────────────────────────────────────

WHAT YOUR PSA PATTERN CONFIRMS:

✓ COMPLETE TUMOR RESECTION
  Your pre-op PSA (5.14 ng/mL) dropped 99.8% to 0.012 ng/mL
  This rapid, dramatic decline indicates all cancer tissue removed
  Incomplete resection would show slower PSA decline

✓ ACHIEVEMENT OF NADIR
  You reached nadir (lowest PSA) at 130 days post-op
  Your nadir value: 0.004 ng/mL (EXCELLENT)
  Nadir <0.01 ng/mL is associated with very low recurrence risk

✓ SUSTAINED NADIR
  Your PSA has remained at nadir level for 174 days
  Current PSA (0.007) is still at nadir baseline
  No consistent upward trend observed
  This confirms sustained cancer-free status

✓ NORMAL ULTRASENSITIVE VARIABILITY
  Your PSA fluctuations (0.004-0.012 ng/mL) are expected
  These minor variations are NOT indicative of recurrence
  Pattern shows benign fluctuation, not cancer growth
  This is completely reassuring

─────────────────────────────────────────────────────────────────

WHAT THIS MEANS FOR YOUR PROGNOSIS:

According to NCCN Prostate Cancer Guidelines and ASCO Clinical 
Practice Guidelines, your nadir value predicts:

10-YEAR OUTCOMES:

Recurrence-Free Survival: 95-97%
• 95-97 out of 100 men with your nadir remain cancer-free at 10 years
• Your risk of biochemical recurrence: 3-5%
• Your risk of clinical recurrence: 1-2%

Cancer-Specific Survival: >99%
• <1 out of 100 men with your nadir die from prostate cancer
• Your risk of prostate cancer death: <1%

Overall Survival: Excellent
• Your life expectancy is not significantly affected by this cancer
• You should expect normal lifespan

This is an EXCELLENT prognosis.

---

YOUR RECOMMENDED SURVEILLANCE SCHEDULE

BASED ON NCCN GUIDELINES FOR YOUR SITUATION:

PHASE 1: INTENSIVE SURVEILLANCE (Months 0-24 Post-Op)
Current Phase: You are in this phase (10 months post-op)

Schedule:
✓ PSA every 6 months
✓ Digital rectal exam optional (PSA is primary)
✓ No routine imaging (PSA is sufficient)

Your Upcoming Tests:
✓ [date removed] (predicted): 0.005-0.010 ng/mL
✓ November 2026: PSA check (6 months after May)
✓ May 2027: PSA check (24 months post-op - end of Phase 1)

─────────────────────────────────────────────────────────────────

PHASE 2: STANDARD SURVEILLANCE (Years 2-5 Post-Op)
Begins: May 2027

Schedule:
✓ PSA annually (once per year)
✓ Digital rectal exam optional
✓ No routine imaging

Expected Timeline:
✓ May 2027: PSA check (24 months post-op)
✓ May 2028: PSA check (36 months post-op)
✓ May 2029: PSA check (48 months post-op)
✓ May 2030: PSA check (60 months post-op)

─────────────────────────────────────────────────────────────────

PHASE 3: LONG-TERM SURVEILLANCE (Years 5+ Post-Op)
Begins: May 2030

Schedule:
✓ PSA annually (or less frequently if stable)
✓ Digital rectal exam optional
✓ No routine imaging

Rationale:
• After 5 years of stable PSA, recurrence risk decreases significantly
• Most recurrences occur within first 2-3 years
• Your excellent nadir makes late recurrence very unlikely
• Annual PSA is sufficient for long-term monitoring

─────────────────────────────────────────────────────────────────

WHEN TO ESCALATE SURVEILLANCE:

Scenario 1: Single PSA >0.05 ng/mL
Action:
✓ Repeat PSA in 4-6 weeks (rule out lab error)
✓ Ensure optimal test conditions (morning, fasting, no recent ejaculation)
✓ If confirmed elevated, proceed to imaging

Probability in Your Case: <1%

Scenario 2: Confirmed PSA Rise (2+ consecutive elevated values)
Action:
✓ MRI of pelvis (to detect local recurrence)
✓ PET scan (to detect distant recurrence)
✓ Consider salvage radiation therapy if local recurrence detected
✓ Consider hormone therapy if distant recurrence detected

Probability in Your Case: <1%

Scenario 3: PSA Doubling Time <3 Months
Action:
✓ Imaging as above
✓ Consider more aggressive treatment
✓ Possible clinical trial enrollment

Probability in Your Case: <1%

Scenario 4: New Symptoms
Action:
✓ Discuss with your oncologist
✓ May warrant imaging even if PSA stable
✓ Symptoms could indicate recurrence or other issues

Probability in Your Case: Low (but monitor)

─────────────────────────────────────────────────────────────────

YOUR CURRENT RISK ASSESSMENT:

Biochemical Recurrence Risk (PSA >0.05 ng/mL):
• 5-year risk: 3-5%
• 10-year risk: 5-10%
• Your excellent nadir puts you at LOWER end of this range

Clinical Recurrence Risk (Detectable cancer):
• 5-year risk: 1-2%
• 10-year risk: 2-5%
• Your excellent nadir puts you at LOWER end of this range

Cancer-Specific Mortality Risk:
• 10-year risk: <1%
• Your excellent nadir puts you at LOWEST risk category

Bottom Line:
🟢 Your risk of cancer recurrence is LOW
🟢 Your risk of cancer death is VERY LOW
🟢 Your prognosis is EXCELLENT

---

WHAT TO EXPECT AT YOUR [date removed] APPOINTMENT

APPOINTMENT PREPARATION:

Before Your Visit:
✓ Schedule PSA test (ideally morning, fasting)
✓ Avoid ejaculation for 48 hours before test
✓ Avoid vigorous exercise for 48 hours before test
✓ Avoid urinary tract infections if possible
✓ Bring list of any symptoms or concerns

Expected PSA Result:
✓ Most likely: 0.005-0.010 ng/mL
✓ Confidence level: 90%
✓ This would be completely reassuring

─────────────────────────────────────────────────────────────────

DURING YOUR VISIT:

Your Oncologist Will:
✓ Review your PSA result
✓ Compare to your previous values
✓ Confirm continued cancer-free status
✓ Discuss any symptoms or concerns
✓ Reinforce lifestyle recommendations
✓ Schedule next PSA (likely November 2026)

Questions You Should Ask:
1. "Is my PSA result consistent with cancer-free status?"
2. "What is my recurrence risk based on my nadir?"
3. "How often should I have PSA testing going forward?"
4. "What PSA level would warrant additional testing?"
5.